AzTrials
AzTrials

Renal Cell CarcinomaPhase 3COSMIC-313NCT03937219

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

A Phase 3 study testing Cabozantinib, Nivolumab and Ipilimumab in people with Renal Cell Carcinoma, run by Exelixis at 159 sites in 25 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Renal Cell Carcinoma
What is being tested?
Cabozantinib, Nivolumab and Ipilimumab
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
855 participants
Where
159 sitesin 25 countries
Study dates
25 Jun 2019to 31 Jan 2027
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.
  • Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.
  • Measurable disease per RECIST 1.1 as determined by the Investigator. Measurable disease must be outside the radiation field if radiation therapy was previously administered.
  • Karnofsky Performance Status (KPS) ≥ 70%.
  • Adequate organ and marrow function.

Who cannot join

  • Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.
  • Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and stable for at least 4 weeks prior to randomization.
  • Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.
  • Administration of a live, attenuated vaccine within 30 days prior to randomization.
  • Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary lesions, or lesions invading major pulmonary blood vessels.
Show all 13Show fewer
  • Other clinically significant disorders such as:
  • Autoimmune disease that has been symptomatic or required treatment within the past two years from the date of randomization.
  • Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.
  • Active infection requiring systemic treatment. Acute or chronic hepatitis B or C infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active myobacterial infection.
  • Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization.
  • Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization. Minor surgeries within 10 days prior to randomization. Subjects must have complete wound healing from major or minor surgery before randomization.
  • Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

Trial locations and contacts

159 sites in 25 countries.

159 sites in 25 countries

United States30 sites

  • Exelixis Clinical Site #3

    Atlanta, Georgia, 30318

  • Exelixis Clinical Site #58A

    Baltimore, Maryland, 21287

  • Exelixis Clinical Site #29

    Boca Raton, Florida, 33486

  • Exelixis Clinical Site #7B

    Boston, Massachusetts, 02114

  • Exelixis Clinical Site #7A

    Boston, Massachusetts, 02215

  • Exelixis Clinical Site #7C

    Boston, Massachusetts, 02215

  • Exelixis Clinical Site #6

    Burlington, Massachusetts, 01805

  • Exelixis Clinical Site #102

    Charleston, South Carolina, 29425

  • Exelixis Clinical Site #101

    Charlotte, North Carolina, 28204

  • Exelixis Clinical Site #95

    Chicago, Illinois, 60612

  • Exelixis Clinical Site #15

    Detroit, Michigan, 48201

  • Exelixis Clinical Site #64

    Fairfax, Virginia, 22031

  • Exelixis Clinical Site #24

    Kansas City, Missouri, 64132

  • Exelixis Clinical Site #116

    La Jolla, California, 92093

  • Exelixis Clinical Site #13

    Madison, Wisconsin, 53792

  • Exelixis Clinical Site #44

    Miami, Florida, 33176

  • Exelixis Clinical Site #5

    Myrtle Beach, South Carolina, 29572

  • Exelixis Clinical Site #10

    Nashville, Tennessee, 37203

  • Exelixis Clinical Site #38

    Nashville, Tennessee, 37232

  • Exelixis Clinical Site #159

    New York, New York, 10032

  • Exelixis Clinical Site #8

    New York, New York, 10065

  • Exelixis Clinical Site #2

    Omaha, Nebraska, 68130

  • Exelixis Clinical Site #166

    Orange, California, 92868-3201

  • Exelixis Clinical Site #12

    Pittsburgh, Pennsylvania, 15232

  • Exelixis Clinical Site #107

    Portland, Oregon, 97239

  • Exelixis Clinical Site #69

    Scarborough, Maine, 04074

  • Exelixis Clinical Site #57

    Seattle, Washington, 98109

  • Exelixis Clinical Site #1

    Spokane, Washington, 99208

  • Exelixis Clinical Site #4

    St Louis, Missouri, 63110

  • Exelixis Clinical Site #19

    Syracuse, New York, 13210

Other trials in United States

France13 sites

  • Exelixis Clinical Site #86

    Bordeaux, 33075

  • Exelixis Clinical Site #71

    Le Mans, 72000

  • Exelixis Clinical Site #78

    Lyon, 69373

  • Exelixis Clinical Site #80

    Montpellier, 34295

  • Exelixis Clinical Site #66

    Nice, 06189

  • Exelixis Clinical Site #150

    Paris, 75015

  • Exelixis Clinical Site #65

    Reims, 51726

  • Exelixis Clinical Site #125

    Rennes, 35042

  • Exelixis Clinical Site #128

    Strasbourg, 67000

  • Exelixis Clinical Site #90

    Strasbourg, 67200

  • Exelixis Clinical Site #42

    Toulouse, 31059

  • Exelixis Clinical Site #67

    Vandœuvre-lès-Nancy, 54519

  • Exelixis Clinical Site #37

    Villejuif, 94800

Other trials in France

Australia11 sites

  • Exelixis Clinical Site #18

    Adelaide, South Australia, 5000

  • Exelixis Clinical Site #32

    Albury, New South Wales, 2640

  • Exelixis Clinical Site #9

    Ballarat, Victoria, 3350

  • Exelixis Clinical Site #23

    Box Hill, Victoria, 3128

  • Exelixis Clinical Site #35

    Kogarah, New South Wales, 2217

  • Exelixis Clinical Site #11

    North Adelaide, South Australia, 5006

  • Exelixis Clinical Site #27

    North Ryde, New South Wales, 2109

  • Exelixis Clinical Site #17

    South Brisbane, Queensland, 4101

  • Exelixis Clinical Site #26

    Subiaco, Western Australia, 6008

  • Exelixis Clinical Site #33

    Sydney, New South Wales, 2065

  • Exelixis Clinical Site #14

    Woolloongabba, Queensland, 4102

Other trials in Australia

Spain11 sites

  • Exelixis Clinical Site #43

    Barcelona, 08035

  • Exelixis Clinical Site #36

    Barcelona, 08036

  • Exelixis Clinical Site #49

    Córdoba, 14004

  • Exelixis Clinical Site #34

    Madrid, 28009

  • Exelixis Clinical Site #94

    Madrid, 28040

  • Exelixis Clinical Site #20

    Madrid, 28041

  • Exelixis Clinical Site #55

    Madrid, 28050

  • Exelixis Clinical Site #96

    Oviedo, 33011

  • Exelixis Clinical Site #45

    Pamplona, Navarre, 31008

  • Exelixis Clinical Site #53

    Santiago de Compostela, Coruña, 15706

  • Exelixis Clinical Site #74

    Valencia, 46009

Other trials in Spain

Brazil9 sites

  • Exelixis Clinical Site #168

    Barretos, São Paulo, 14784-400

  • Exelixis Clinical Site #154

    Belo Horizonte, Minas Gerais, 30130-090

  • Exelixis Clinical Site #155

    Curitiba, Paraná, 80530-010

  • Exelixis Clinical Site #158

    Porto Alegre, Rio Grande do Sul, 90050-170

  • Exelixis Clinical Site #140

    Porto Alegre, Rio Grande do Sul, 90110-270

  • Exelixis Clinical Site #163

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Exelixis Clinical Site #162

    São José do Rio Preto, São Paulo, 15090-000

  • Exelixis Clinical Site #119

    São Paulo, 01323-001

  • Exelixis Clinical Site #141

    São Paulo, 01327-001

Other trials in Brazil

Germany8 sites

  • Exelixis Clinical Site #124

    Dresden, 01307

  • Exelixis Clinical Site #117

    Frankfurt am Main, Hesse, 60596

  • Exelixis Clinical Site #127

    Heidelberg, Baden-Wurttemberg, 69120

  • Exelixis Clinical Site #137

    Jena, Thuringia, 077477

  • Exelixis Clinical Site #164

    Mainz, Rhineland-Palatinate, 55131

  • Exelixis Clinical Site #139

    Münster, North Rhine-Westphalia, 48149

  • Exelixis Clinical Site #171

    Münster, North Rhine-Westphalia, 90419

  • Exelixis Clinical Site #115

    Tübingen, Baden-Wurttemberg, 72076

Other trials in Germany

Italy8 sites

  • Exelixis Clinical Site #47

    Arezzo, 52100

  • Exelixis Clinical Site #70

    Faenza, Ravenna, 48018

  • Exelixis Clinical Site #41

    Meldola, Forli - Cesena, 47014

  • Exelixis Clinical Site #60

    Modena, 41124

  • Exelixis Clinical Site #61

    Padova, 35128

  • Exelixis Clinical Site #59

    Pavia, 27100

  • Exelixis Clinical Site #104

    Perugia, 06132

  • Exelixis Clinical Site #68

    Terni, 05100

Other trials in Italy

Mexico8 sites

  • Exelixis Clinical Site #123

    Aguascalientes, Aguascalientes, 20116

  • Exelixis Clinical Site #167

    León, Guanajuato, 37000

  • Exelixis Clinical Site #160

    Mexico City, 03100

  • Exelixis Clinical Site #134

    Monterrey, Nuevo León, 64710

  • Exelixis Clinical Site #132

    Oaxaca City, Oaxaca, 68000

  • Exelixis Clinical Site #131

    Querétaro, 76000

  • Exelixis Clinical Site #161

    Querétaro, 76090

  • Exelixis Clinical Site #169

    Zapopan, Jalisco, 45070

Other trials in Mexico

Argentina7 sites

  • Exelixis Clinical Site #54

    Buenos Aires, C1125ABD

  • Exelixis Clinical Site #63

    CABA, C1120AAT

  • Exelixis Clinical Site #110

    Ciudad Autonoma de Buenos Aire, C1426ANZ

  • Exelixis Clinical Site #120

    Córdoba, X5004

  • Exelixis Clinical Site #153

    Pilar, Buenos Aires, B1629ODT

  • Exelixis Clinical Site #109

    Rosario, Santa Fe Province, S2000KZE

  • Exelixis Clinical Site #73

    San Miguel de Tucumán, Tucumán Province, T4000

Other trials in Argentina

Israel6 sites

  • Exelixis Clinical Site #88

    Beersheba, 84101

  • Exelixis Clinical Site #81

    Haifa, 3109601

  • Exelixis Clinical Site #84

    Jerusalem, 9112001

  • Exelixis Clinical Site #121

    Kfar Saba, 4428164

  • Exelixis Clinical Site #97

    Petah Tikva, 49100

  • Exelixis Clincal Site #129

    Ramat Gan, 5265601

Other trials in Israel

Canada5 sites

  • Exelixis Clinical Site #22

    Calgary, Alberta, T2N 4N2

  • Exelixis Clinical Site #113

    Montreal, Quebec, H3T 1E2

  • Exelixis Clinical Site #46

    Ottawa, Ontario, K1H 8L6

  • Exelixis Clinical Site #25

    Toronto, Ontario, M4N 3M5

  • Exelixis Clinical Site #105

    Winnipeg, Manitoba, R3E 0V9

Other trials in Canada

Poland5 sites

  • Exelixis Clinical Site #31

    Biała Podlaska, 21-500

  • Exelixis Clinical Site #62

    Bydgoszcz, 85-796

  • Exelixis Clinical Site #135

    Gdansk, 80-219

  • Exelixis Clinical Site #99

    Otwock, 05-400

  • Exelixis Clinical Site #83

    Poznan, 60-693

Other trials in Poland

United Kingdom5 sites

  • Exelixis Clinical Site #72

    Cambridge, CB2 0QQ

  • Exelixis Clinical Site #93

    Glasgow, G12 0YN

  • Exelixis Clinical Site #30

    London, EC1A 7BE

  • Exelixis Clinical Site #172

    London, W6 8RF

  • Exelixis Clinical Site #92

    Manchester, M20 4BX

Other trials in United Kingdom

Austria4 sites

  • Exelixis Clinical Site #76

    Linz, Upper Austria, 4020

  • Exelixis Clinical Site #75

    Salzburg, 5020

  • Exelixis Clinical Site #126

    Vienna, 1090

  • Exelixis Clinical Site #98

    Wiener Neustadt, Lower Austria, 2700

Other trials in Austria

South Korea4 sites

  • Exelixis Clinical Site #147

    Seongnam-si, Gyeonggi-do, 13620

  • Exelixis Clinical Site #143

    Seoul, 03722

  • Exelixis Clinical Site #151

    Seoul, 05505

  • Exelixis Clinical Site #152

    Seoul, 06351

Other trials in South Korea

Chile3 sites

  • Exelixis Clinical Site #91

    Santiago, 7500921

  • Exelixis Clinical Site #100

    Santiago, 8420383

  • Exelixis Clinical Site #85

    Temuco, Región de La Araucanía (IX), 4810561

Other trials in Chile

Czechia3 sites

  • Exelixis Clinical Site #89

    Králová, 50005

  • Exelixis Clinical Site #114

    Prague, 140 59

  • Exelixis Clinical Site #118

    Prague, 150 06

Other trials in Czechia

Finland3 sites

  • Exelixis Clinical Site #50

    Helsinki, 00029

  • Exelixis Clinical Site #56

    Tampere, 33520

  • Exelixis Clinical Site #52

    Turku, 20520

Other trials in Finland

Hong Kong3 sites

  • Exelixis Clinical Site #28

    Hong Kong

  • Exelixis Clinical Site #136

    Shatin

  • Exelixis Clinical Site #111

    Tuenmen

Other trials in Hong Kong

Taiwan3 sites

  • Exelixis Clinical Site #142

    Taichung, 404

  • Exelixis Clinical Site #138

    Taipei, 10002

  • Exelixis Clinical Site #173

    Taoyuan, 333

Other trials in Taiwan

Belgium2 sites

  • Exelixis Clinical Site #112

    Brussels, 1000

  • Exelixis Clinical Site #146

    Hasselt, 3500

Other trials in Belgium

Hungary2 sites

  • Exelixis Clinical Site #39

    Budapest, 1122

  • Exelixis Clinical Site #51

    Pécs, 7624

Other trials in Hungary

Netherlands2 sites

  • Exelixis Clinical Site #144

    Amsterdam, 1105 AZ

  • Exelixis Clinical Site #149

    Rotterdam, 3015 GD

Other trials in Netherlands

New Zealand2 sites

  • Exelixis Clinical Site #122

    Hamilton, Waikato Region, 3204

  • Exelixis Clinical Site #148

    Newtown, Wellington Region, 6021

Other trials in New Zealand

Singapore2 sites

  • Exelixis Clinical Site #77

    Singapore, 119074

  • Exelixis Clinical Site #40

    Singapore, 169610

Other trials in Singapore

About this study

Official title: A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.

Read the detailed description

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration of progression-free survival (PFS) versus nivolumab and ipilimumab. A secondary objective is to evaluate the effect of triplet combination on the duration of overall survival (OS).

Being tested
Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
Keywords
renal, cancer, carcinoma
Medical subject headings
Carcinoma, Renal Cell, Neoplasms, Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CabozantinibDrug

    Also called Cabometyx, XL184

    Specified dose on specified days.

  • NivolumabBiological

    Also called Opdivo, BMS-936558

    Specified dose on specified days.

  • IpilimumabBiological

    Also called Yervoy, BMS-734016

    Specified dose on specified days.

  • Cabozantinib-matched placeboDrug

    Specified dose on specified days.

Study groups in NCT03937219
Study groupRoleWhat they receive
Experimental ArmExperimentalCabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
Receives: Drug: Cabozantinib; Biological: Nivolumab; Biological: Ipilimumab
Control ArmActive comparatorCabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
Receives: Biological: Nivolumab; Biological: Ipilimumab; Drug: Cabozantinib-matched placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)

    Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause. PFS (months) = (earliest date of progression, death, censoring - date of randomization + 1)/30.4375. PFS was determined as per Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1.

    Measured: Up to 32 months

Secondary outcomes (1)

  1. Duration of Overall Survival (OS)

    Duration of OS (months) = (earliest date of death or censoring - date of randomization + 1)/30.4375.

    Measured: Up to 58 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 May 2019
  2. Study start25 Jun 2019
  3. Primary completion31 Jan 2022
  4. Study completion31 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
855 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03937219
Sponsor's protocol ID
XL184-313
Other IDs
2024-515616-47-00
Acronym
COSMIC-313
Status last verified
Sep 2026
First submitted
2 May 2019
Last updated
20 Oct 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.

    PubMed 37163623

  • Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available.

    PubMed 35383907

  • Mar N, Kaakour D, Rezazadeh Kalebasty A. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract. 2022 Mar;18(3):197-199. doi: 10.1200/OP.21.00446. Epub 2021 Sep 22. No abstract available.

    PubMed 34550754

  • Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2.

    PubMed 33058158

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Cabozantinib, Nivolumab and Ipilimumab in people with Renal Cell Carcinoma, run by Exelixis at 159 sites in 25 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 159 sites in United States, France, Australia, Spain, Brazil and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Sep 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC) (time frame: Up to 32 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03937219, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in